✦ LIBER ✦

Phase I/II trials of WR-2721 and cis-platinum

✍ Scribed by Donna Glover; John H. Glick; Clare Weiler; Kevin Fox; Andrew Turrisi; Morton M. Kligerman

Publisher: Elsevier Science
Year: 1986
Tongue: English
Weight: 528 KB
Volume: 12
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(86)90205-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trials of WR-2721 and cis-platin

Phase I trials of WR-2721 and cis-platinum

✍ Donna Glover; John H. Glick; Clare Weiler; John Yuhas; Morton M. Kligerman 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 477 KB

Phase I Controlled trials of WR-2721 and

Phase I Controlled trials of WR-2721 and cyclophosphamide

✍ John H. Glick; Donna Glover; Clare Weiler; Lorraine Norfleet; John Yuhas; Morton 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 506 KB

Phase I trials of WR2721 in combination

Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum

✍ Morton M. Kligerman; John H. Glick; Harold I. Amols; John M. Yuhas 📂 Article 📅 1981 🏛 Elsevier Science 🌐 English ⚖ 106 KB

Phase I clinical trials of WR-2721 with

Phase I clinical trials of WR-2721 with alkylating agent chemotherapy

✍ John H. Glick; Donna J. Glover; Clare Weiler; Albert Blumberg; Diana Nelson; Joh 📂 Article 📅 1982 🏛 Elsevier Science 🌐 English ⚖ 710 KB

Topical application of WR-2721 to preven

Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A phase I/II trial

✍ Gusfavo S. Montana; Mitchell S. Anscher; Charles M. Mansbach II; Nicolas Duly; M 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 439 KB

Patients undergoing x-ray therapy to the pelvis have intestinal symptoms proportional to the volume treated and the dose delivered. WR-2721, S-2 (3-aminopropylaminoethyl) phosphorothioic acid, is an organic thiophosphate compound that selectively protects normal tissues against radiation effects. A

Phase I-II trial of percutaneous intra-a

Phase I-II trial of percutaneous intra-arterial Cis-diamminedichloro platinum (II) for regionally confined malignancy

✍ D. B. Calvo III; Y. Z. Patt; S. Wallace; V. P. Chuang; R. S. Benjamin; J. D. Pri 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 539 KB

Forty-nine patients with regionally confined recurrent malignancy were treated with intra-arterial cisdiamminedichloro platinum I1 in a Phase 1-11 trial. A safe starting dose of 120 mg/m\* was established. An overall response rate of 45% was noted with significant responses observed among patients w